1. Scrip
  2. >>R&D

Cipla Chief Calls For Invigorating Focus On Repurposed Drugs

 
• By Anju Ghangurde

Cipla chairman underscores the potential and value of repurposing drugs for Indian researchers and pharma firms looking to build their R&D activities, amid signs of growing attention to the promising area globally.

Fish
REPURPOSING MEDICINES IS A PROMISING AREA TO FOCUS ON , SAYS CIPLA'S HAMIED • Source: Shutterstock

Cipla Ltd.’s chairman Dr Yusuf Hamied recently doled out some important advice to researchers at India’s Tata Institute of Fundamental Research (TIFR) – don’t ignore the potential of repurposing or repositioning of drugs.

Hamied, in an address at the institute, said that repurposing was emerging as a promising approach to overcome the hurdles...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.